Chandi Prasad Ravipati
Lara Elize Lamigo-Itao
Due to increasing healthcare expenditure, advancing vaccine technology, and rising demand for preventive vaccines, especially new COVID-19 vaccines, the Asia-Pacific preventive vaccines market will rise by 12.89% annually with a total addressable market cap of $97.2 billion between 2020 and 2026.
Coronavirus infection has recently infected millions of people all over the world. In certain areas, community transmission has resulted in an increase in global casualties. At present, Big pharma and biopharma are concentrating their efforts on COVID-19 vaccine research and development. The COVID-19 pandemic situation has generated unprecedented demand, and companies are heavily investing in R&D activities, with government support as well as technological advancement to shorten the clinical trial duration and increase production efficiency. The market's growth prospects will be bolstered by the expansion of vaccine manufacturing facilities to meet the rising demand.
Vaccine World Asia Congress 2022 will be the only vaccine-focused platform in Asia that will bring together global partners and regional stakeholders to leverage partnership opportunities, learn about the latest technological advancements and spearhead scientific innovation. The event will play host to the Big Pharmas, International Biopharma, Asian Biopharma, Academic & Research Institutes, Regulatory Authorities, NGOs, Solution Providers, and Technocrats.
With this edition of Vaccine World Asia, we have co-located with Asia-Pacific Vaccine Excellence Awards. If Asia’s vaccine business matters to you, then Vaccine World Asia Congress 2022 is the place to be!
Asia Pacific Vaccine Excellence Award applauds extraordinary leaders & trendsetters of today and inspires the innovators of tomorrow. The Awards Ceremony will be held in conjunction with the 4th Annual Vaccines World Asia Congress 2022 Virtual Conference.
In this webcast, our panellists will discuss the disruptive potential of the newly emerged mRNA platform in the vaccine industry. If it is making a big enough impact in becoming the main vaccine development platform or will become used an alternative method for rapid vaccine development.
We will discuss the main differences between the mRNA platform against other pre-existing technologies, the pros and cons, the advantages of mRNA vaccines over DNA-based vaccines (eg. shelf life, storage requirements, development timeframes), disruptive potential of mRNA platform on raw materials and vaccines supply and demand and what to expect in the international and local regulatory landscape.
This will be a great chance for you to gain insights from panellists with high level positions and expert knowledge in the vaccine industry.
Vaccine World Asia Congress will be the only vaccine focused platform in Singapore for Asia that will bring together global partners and regional stakeholders to leverage partnership opportunities, learn about the latest technological advancements and spearhead scientific innovation. The event will play host to the BIG Pharmas, International Biopharma’s, Asian Biopharmas, Academic & Research Institutes, Regulatory Authorities, NGOs, Solution Providers and Technocrats. If Asia’s vaccines business matters to you, then Vaccine World Asia 2022 is the place to be!
Plenary Sessions: The Future of the Vaccine Industry after COVID-19
Vaccine Manufacturing Pandemic Preparedness
Vaccine Modalities & Innovations
Innovation in Vaccine Delivery
Plenary Sessions: Covid-19 Vaccine Updates
Vaccine R&D Excellence
Vaccine Manufacturing Best Practices
Vaccine Quality & Supply Chain Management
360biolabs, a BioAgilytix company, offers the full spectrum of bioanalytical lab services for small and large molecules in all phases of drug development, with the added benefits that come from conducting your early phase clinical trials in Australia.
As APAC’s most comprehensive speciality laboratory, we provide a single laboratory for all of your global clinical trial requirements. We support pharmacokinetic (PK) analysis (biologics, small molecules, peptides and proteins), a diverse range of pharmacodynamic (PD) endpoints (flow cytometry, biomarkers, molecular assays, ELISPOT, virological endpoints including neutralisation) and central lab services in a quality assured environment (GLP, GCP, ISO / IEC 17025). As BioAgilytix LLC’s Australian subsidiary, we provide a single solution for your global clinical trial requirements with laboratories in USA and Europe as well as Australia.
Zuellig Pharma is one of the largest healthcare services groups in Asia and our purpose is to make healthcare more accessible. We provide world-class distribution, digital and commercial services to support the growing healthcare needs in this region. The company was started a hundred years ago and has grown to become a US$15 billion business covering 13 markets with over 13,000 employees. Our people serve over 350,000 medical facilities and work with over 1,000 clients, including the top 10 pharmaceutical companies in the world.
More recently, we launched our Zuellig Health Solutions Innovation Centre to develop new services and address some pressing healthcare needs in Asia. Since then, our teams have been focused on creating data, digital and disease management solutions, supporting patients with chronic conditions and helping payors manage healthcare costs.
WuXi Vaccines (https://www.wuxibiologics.
Peli BioThermal is the first cold chain packaging solutions provider to make available a broad and comprehensive portfolio of patented and award-winning single-use and reusable thermal protection packaging solutions for the safe transport of pharmaceuticals, clinical trials, diagnostics, tissue, vaccines and blood supplies for the life science industry.
Collaboration with our clients is the first step to ensure we provide a solution that is built around the unique and very specific needs of your temperature-sensitive payloads. Our global services network provides consultation, support, engineering and deployment for your cold chain distribution challenges wherever they exist.
Peli BioThermal designs products to ensure our customers valuable payloads are kept in perfect condition, irrespective of external temperatures and conditions. They are designed to be strong and robust, to survive the rigors of international transport. With environmental issues in mind, we ensure that our design team specify the correct materials and consider ‘end of life’ recycling for all of our ranges, whether they are single use or reusable packaging systems.
By leveraging FUJIFILM Group’s collective bio-related technologies, including Wako Pure Chemical and Irvine Scientific,FUJIFILM continues to accelerate the growth and provide broad product portfolio in bio-medical through synergies and collaborations.
FUJIFILM Wako Pure Chemical (FFWK) is a world-wide supplier of high purity chemicals and reagents based in Japan.
FFWK has various raw materials including cell culture media for vaccine production and QC/QA testing products,and provides services to support the process from the research stage to the commercial stage of pharmaceutical manufacturing.
SaniSure is a global leader in the design and manufacturing of single-use systems and components for drug and vaccine manufacturing and other biotech and pharmaceutical applications. With the consolidation of several strategic acquisitions under one integrated roof, the combined resources, competencies and ability to create value for customers is unmatched in the industry. SaniSure’s core manufacturing capabilities include cleanroom assembly, fabrication, injection molding, injection stretch blow molding, tubing extrusion, filling-needle manufacturing, and many additional proprietary technologies.
SaniSure offers a wide range of single-use technology systems and components including Mixed4Sure™ mixing solutions, complex sterile assemblies, PharmaTainer™ bottles and carboys, Cap2V8® bottle closures, Pharma-Clear® Silicone Tubing, Cellgyn® TPE tubing, Pharma- Line™ tubing, aSURE® fittings, and many more.
SaniSure has a growing global footprint of five engineering and manufacturing sites worldwide to provide customers with an unrivaled level of innovation, quality, and vertical integration/supply-chain security.
Incorporated in 2009, CanSinoBIO (SSE: 688185, HKEX: 06185) commits to provide high-quality, innovative, and accessible vaccines for global public health security. It possesses five integrated platform technologies upon which the company has established a robust pipeline of 17 vaccines preventing 12 diseases, including the world's initial vaccine for Ebola virus disease Ad5-EBOV, the Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) approved in over 10 countries and granted EUL by the WHO, the Group A and Group C Meningococcal Conjugate Vaccine (CRM197) Menphecia and the Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) Menhycia approved by NMPA in China. Recently, our pioneering inhaled COVID-19 vaccine Convidecia Air has been approved as booster dose in China. Additional information can be found online at www.cansinotech.com.
Everything began with a commitment to serve the life sciences and healthcare industries by offering global transport and innovative temperature-controlled logistics solutions. Being one of the market leaders in our sector and dedicated to the clinical trial and cell & gene therapy communities, we are operating in more than 150 countries intending to improve the health of people around the world. Truly focused on our customer and patient needs, we, through a dedicated team, plan, manage and implement a tailor-made temperature-controlled solution to fit your requirements and business goals. Count on us to deliver your life-saving goods worldwide - Count on CRYOPDP!
CRYOPDP video: https://www.youtube.
Founded in 1993, Brand Institute (BI) was created on this principle: provide the highest quality name development services, produced and presented by the most experienced professionals, in a timely manner, and at a competitive price. As we strive to deliver industry-leading nomenclature services, we are constantly adapting to our clients’ needs to deliver greater value and successful outcomes.
SkyCell is a purpose-led technology company transforming the pharmaceutical supply chain through a combination of proprietary software, hardware, and big data. It is the leading manufacturer of temperature-controlled door-to-door container solutions that allow pharma companies to optimise their supply chain by reducing, and even predicting, the risks associated with delivering sensitive drugs by air. Its SaaS solution, SkyCell SECURE, enables pharma companies to have real-time, end-to-end oversight of every shipment around the world, and its automated approval capability reduces quality approval time from an average of 14 days to just hours, getting life-changing drugs to consumers faster.
Designed with sustainability as a core principle, SkyCell’s technologies protect healthcare systems by reducing in-transit failure rate to a market-leading low of less than 0.1% temperature excursions and reduce the CO2 impact of each shipment by almost half the average rate. SkyCell is operationally climate-neutral today and has committed to the goal of end-to-end climate neutrality by 2040. SkyCell’s sustainability targets are science led and aligned to both the Paris Agreement and UN sustainable development goals.
Roquette is a family-owned global leader in plant-based ingredients, a pioneer of plant proteins and a leading provider of pharmaceutical excipients. Founded in 1933, the company currently operates in more than 100 countries.
Life and nature have been our sources of inspiration for decades. All our raw materials are of natural origin. From them, we offer pharmaceutical solutions that play a key role in medical treatments. We truly unlock the potential of nature to improve, cure and save lives.
Discover the Pharma Virtual Lab by Roquette
With more than 130 years of experience, Dr. Paul Lohmann® is a German expert in salt manufacturing and provides DPL-BioPharm Salts for the biopharmaceutical industry. These salts act as nutrients for cell cultures, as buffering and post-harvest processing agents within upstream processing. For downstream processing various acetates, citrates, phosphates and sulfates enable efficient bioprocesses for separation, precipitation and purification.
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines, and diagnostics. The company employs an application-oriented development strategy, with a particular focus on product design, quality control and solution-based support. Our products and services enable anyone in the field of drug development to have a more intuitive and streamlined process.
ACROBiosystems' catalog includes a comprehensive list of disease-associated biomarkers and drug targets from humans to other common species. All of our products are produced with high quality and batch-to-batch consistency to satisfy the rigorous standards of pharmaceutical research and development.
As ACROBiosystems' only distributor in India, Allianz BioInnovation is an ISO 9001: 2015 Certified Biotech company offering innovative Life Science Research tools from renowned companies across the world who are world leaders in their respective fields. The company has gained recognition, success and growth to its present position of a leading distributor as a result of our focus on scientist’s research needs and by following three principle viz; value, service and support.
URL link/website: https://www.acrobiosystems.com/
Datwyler is a leading industrial supplier and a key player in the global health care world.
Our state-of-the-art solutions for drug packaging and medical devices, build on over 100 years of experience. Within our healthcare offering, we provide a unique range of products and services including the most advanced elastomer formulations, coatings, aluminum
seals, and processing technologies. Partnering up with the world’s top pharmaceutical and medical companies, we are a vital link and stand by our mission to ensure all patient’s safety and improve patients’ lives.
For more infromation, please visit: https://datwyler.com/
Cold Chain Platform (CCP) is 100% focused on cold chain and logistics in the biopharmaceutical, life science, and healthcare industries. CCP services help global companies reach the right partners and get a firm foothold in the Asia Pacific. CCP works with global organizations to help them gain access to the APAC cold chain, logistics, and pharmaceutical market through a highly targeted audience.
BioPharma Asia aims to keep its readers abreast of all developments in the areas of Manufacturing, Development, Quality Assurance, Outsourcing, and Regulatory Affairs, with only the highest quality articles and webinars written and presented by the most respected authors/presenters, associated with only end-user companies. This ensures that the information will always be guaranteed to remain timely, informative and above all totally unbiased.
P95 is a global company with a headquarter in Belgium. Our local and regional offices are located in the Netherlands and Colombia, soon in Thailand.
P95 delivers cutting-edge expertise in epidemiology and pharmacovigilance. We are passionate about healthcare and help our customers with innovative medical research.
Our team is comprised of epidemiologists, pharmacovigilance specialists, biostatisticians, data scientists, medical writers, IT engineers and project managers. We are an international team working from more than 17 countries.
P95 projects are largely focused on a broad range of infectious diseases and vaccines. However, we offer customized services upon request.
Present your expertise to the key vaccines stakeholders from developing economies through a variety of available speaking packages.
Join the exhibition, and build an impressive presence among your potential clients.
Emphasize on your messages by promoting your brand alongside exhibition and thought leadership.
Engage with and build lasting connections that matter the most to your business.
Gain exclusive access to contacts of high-profile attendees through intimate networking opportunities.